QCARE PHARMA CONSULT: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
QCARE PHARMA CONSULT
Largest movements
- Cash -€36,144
down €36,144 (-38.6%), from €93,737 to €57,593
mainly Other debts (-€45,022) and Contributions, distributions and other (-€24,500)
- Receivables within one year -€5,322
down €5,322 (-24.3%), from €21,945 to €16,623
of which Other amounts receivable: -€9,094
- Other debts -€45,022
down €45,022 (-57.5%), from €78,290 to €33,268
- Tax, wage and social debts +€13,424
up €13,424 (+196%), from €6,840 to €20,264
- Profit (loss) carried forward -€10,182
down €10,182 (-94.3%), from €10,803 to €621
- Other operating charges +€49,715
up €49,715 (+11,482%), from €433 to €50,148
- Gross operating margin -€35,294
down €35,294 (-32.5%), from €108,536 to €73,242
- Taxes -€19,009
down €19,009 (-72.7%), from €26,158 to €7,149
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €117,268 | €75,735 | -€41,533 | -35.4% |
| Fixed assets | 21/28 | €1,586 | €484 | -€1,102 | -69.5% |
| Tangible fixed assets | 22/27 | €1,586 | €484 | -€1,102 | -69.5% |
| Furniture and vehicles | 24 | €1,586 | €484 | -€1,102 | -69.5% |
| Current assets | 29/58 | €115,682 | €75,251 | -€40,431 | -35.0% |
| Amounts receivable within one year | 40/41 | €21,945 | €16,623 | -€5,322 | -24.3% |
| Trade receivables | 40 | - | €3,772 | +€3,772 | |
| Other amounts receivable | 41 | €21,945 | €12,851 | -€9,094 | -41.4% |
| Cash at bank and in hand | 54/58 | €93,737 | €57,593 | -€36,144 | -38.6% |
| Deferred charges and accrued income | 490/1 | - | €1,035 | +€1,035 | |
| Total equity and liabilities | 10/49 | €117,268 | €75,735 | -€41,533 | -35.4% |
| Equity | 10/15 | €23,203 | €13,021 | -€10,182 | -43.9% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Profit (loss) carried forward | 14 | €10,803 | €621 | -€10,182 | -94.3% |
| Amounts payable | 17/49 | €94,065 | €62,714 | -€31,351 | -33.3% |
| Amounts payable within one year | 42/48 | €94,065 | €62,714 | -€31,351 | -33.3% |
| Current portion of amounts payable after more than one year | 42 | €6,760 | €6,730 | -€30 | -0.4% |
| Trade debts | 44 | €2,175 | €2,452 | +€277 | +12.7% |
| Suppliers | 440/4 | €2,175 | €2,452 | +€277 | +12.7% |
| Taxes, remuneration and social security | 45 | €6,840 | €20,264 | +€13,424 | +196% |
| Taxes | 450/3 | €6,840 | €20,264 | +€13,424 | +196% |
| Other amounts payable | 47/48 | €78,290 | €33,268 | -€45,022 | -57.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,427 | €1,103 | -€324 | -22.7% |
| Other operating charges | 640/8 | €433 | €50,148 | +€49,715 | +11,482% |
| Gross operating margin | 9900 | €108,536 | €73,242 | -€35,294 | -32.5% |
| Operating profit (loss) | 9901 | €106,676 | €21,991 | -€84,685 | -79.4% |
| Financial charges | 65/66B | €486 | €524 | +€38 | +7.8% |
| Recurring financial charges | 65 | €486 | €524 | +€38 | +7.8% |
| Profit (loss) for the period before taxes | 9903 | €106,190 | €21,467 | -€84,723 | -79.8% |
| Income taxes | 67/77 | €26,158 | €7,149 | -€19,009 | -72.7% |
| Profit (loss) for the period | 9904 | €80,032 | €14,318 | -€65,714 | -82.1% |
| Profit (loss) for the period to be appropriated | 9905 | €80,032 | €14,318 | -€65,714 | -82.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.